JP2009514910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009514910A5 JP2009514910A5 JP2008539299A JP2008539299A JP2009514910A5 JP 2009514910 A5 JP2009514910 A5 JP 2009514910A5 JP 2008539299 A JP2008539299 A JP 2008539299A JP 2008539299 A JP2008539299 A JP 2008539299A JP 2009514910 A5 JP2009514910 A5 JP 2009514910A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- combination
- inhibitor
- pulmonary hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 150000003815 prostacyclins Chemical class 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 102000002045 Endothelin Human genes 0.000 claims description 3
- 108050009340 Endothelin Proteins 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 230000004872 arterial blood pressure Effects 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 3
- 210000001147 pulmonary artery Anatomy 0.000 claims description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 229940043355 kinase inhibitor Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229940122858 Elastase inhibitor Drugs 0.000 claims 2
- 229940097217 cardiac glycoside Drugs 0.000 claims 2
- 239000002368 cardiac glycoside Substances 0.000 claims 2
- 239000003602 elastase inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 229930002534 steroid glycoside Natural products 0.000 claims 2
- 150000008143 steroidal glycosides Chemical class 0.000 claims 2
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 1
- 229960003065 bosentan Drugs 0.000 claims 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 229940080856 gleevec Drugs 0.000 claims 1
- -1 hydrate Substances 0.000 claims 1
- 229960002240 iloprost Drugs 0.000 claims 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical group C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 229960002578 sitaxentan Drugs 0.000 claims 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960000835 tadalafil Drugs 0.000 claims 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 1
- 229960005032 treprostinil Drugs 0.000 claims 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims 1
- 229960002381 vardenafil Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05024509.1 | 2005-11-10 | ||
| EP05024509 | 2005-11-10 | ||
| EP05027450.5 | 2005-12-15 | ||
| EP05027450 | 2005-12-15 | ||
| EP06012234 | 2006-06-14 | ||
| EP06012234.8 | 2006-06-14 | ||
| PCT/EP2006/010406 WO2007054216A1 (en) | 2005-11-10 | 2006-10-30 | Diaryl urea for treating pulmonary hypertension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009514910A JP2009514910A (ja) | 2009-04-09 |
| JP2009514910A5 true JP2009514910A5 (https=) | 2009-05-21 |
| JP5084736B2 JP5084736B2 (ja) | 2012-11-28 |
Family
ID=37622057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539299A Expired - Fee Related JP5084736B2 (ja) | 2005-11-10 | 2006-10-30 | 肺高血圧を処置するためのジアリールウレア |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100035888A1 (https=) |
| EP (1) | EP1948170A1 (https=) |
| JP (1) | JP5084736B2 (https=) |
| KR (1) | KR20080067000A (https=) |
| AR (1) | AR057849A1 (https=) |
| AU (1) | AU2006312714A1 (https=) |
| BR (1) | BRPI0618522A2 (https=) |
| CA (1) | CA2628849A1 (https=) |
| CR (1) | CR9953A (https=) |
| EC (1) | ECSP088430A (https=) |
| GT (1) | GT200800058A (https=) |
| IL (1) | IL191178A0 (https=) |
| NO (1) | NO20082498L (https=) |
| PE (1) | PE20070806A1 (https=) |
| SV (1) | SV2009002900A (https=) |
| TW (1) | TW200733961A (https=) |
| UY (1) | UY29903A1 (https=) |
| WO (1) | WO2007054216A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158985B1 (en) * | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| AU2004212633B2 (en) * | 2003-02-21 | 2010-12-09 | ResMed Pty Ltd | Nasal assembly |
| US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1636585B2 (en) * | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| DK1797038T3 (da) * | 2004-09-29 | 2012-09-03 | Bayer Pharma AG | Termodynamisk stabil form af bay 43-9006-tosylat |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| CA2675980C (en) * | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Use of dast for treatment of cancers with acquired resistance to kit inhibitors |
| JP2011525503A (ja) * | 2008-06-25 | 2011-09-22 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全を処置するためのジアリールウレア |
| CN103079567A (zh) * | 2010-04-17 | 2013-05-01 | 拜尔健康护理有限责任公司 | 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物 |
| US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
| GB2503181A (en) * | 2011-03-14 | 2013-12-18 | Cellworks Res India Private Ltd | Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1478358T1 (sl) * | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US7888341B2 (en) * | 2002-04-10 | 2011-02-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer |
| EP1636585B2 (en) * | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) * | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP1850852A4 (en) * | 2005-02-22 | 2009-11-18 | Cedars Sinai Medical Center | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE |
-
2006
- 2006-10-30 BR BRPI0618522-3A patent/BRPI0618522A2/pt not_active IP Right Cessation
- 2006-10-30 WO PCT/EP2006/010406 patent/WO2007054216A1/en not_active Ceased
- 2006-10-30 EP EP06818314A patent/EP1948170A1/en not_active Withdrawn
- 2006-10-30 KR KR1020087013800A patent/KR20080067000A/ko not_active Withdrawn
- 2006-10-30 AU AU2006312714A patent/AU2006312714A1/en not_active Abandoned
- 2006-10-30 JP JP2008539299A patent/JP5084736B2/ja not_active Expired - Fee Related
- 2006-10-30 US US12/084,662 patent/US20100035888A1/en not_active Abandoned
- 2006-10-30 CA CA002628849A patent/CA2628849A1/en not_active Abandoned
- 2006-10-31 AR ARP060104767A patent/AR057849A1/es not_active Application Discontinuation
- 2006-11-07 UY UY29903A patent/UY29903A1/es not_active Application Discontinuation
- 2006-11-09 TW TW095141431A patent/TW200733961A/zh unknown
- 2006-11-09 PE PE2006001406A patent/PE20070806A1/es not_active Application Discontinuation
-
2008
- 2008-05-01 IL IL191178A patent/IL191178A0/en unknown
- 2008-05-06 SV SV2008002900A patent/SV2009002900A/es not_active Application Discontinuation
- 2008-05-06 CR CR9953A patent/CR9953A/es not_active Application Discontinuation
- 2008-05-06 GT GT200800058A patent/GT200800058A/es unknown
- 2008-05-07 EC EC2008008430A patent/ECSP088430A/es unknown
- 2008-06-04 NO NO20082498A patent/NO20082498L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009514910A5 (https=) | ||
| JP2006298933A5 (https=) | ||
| JP2015520738A5 (https=) | ||
| JP2011518833A5 (https=) | ||
| JP2007522220A5 (https=) | ||
| JP2006524660A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP2016528300A5 (https=) | ||
| JP2003531118A5 (https=) | ||
| HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| MA30433B1 (fr) | Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires | |
| JP2013542256A5 (https=) | ||
| JP2009543795A5 (https=) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| FI3609886T3 (fi) | Bentsoatsepiinianalogeja brutonin tyrosiinikinaasia estävinä aineina | |
| MA30704B1 (fr) | Compositions therapeutiques | |
| AR057849A1 (es) | Dialurrea para el tratamiento de hipertension pulmonar | |
| EA022994B1 (ru) | Способ подавления толерантности к опиоидному анальгетику | |
| JP2008513510A5 (https=) | ||
| JP2019151627A5 (https=) | ||
| JP2009511450A5 (https=) | ||
| JP2016531846A5 (https=) | ||
| WO2020236690A9 (en) | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | |
| JP2009040767A5 (https=) | ||
| TW200735874A (en) | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |